Treatment of central nervous system leukemia with intrathecal cytosine arabinoside.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D004285:Dogs; D005260:Female; D000882:Haplorhini; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008578:Meninges; D008875:Middle Aged; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine